NCT02363829View on ClinicalTrials.gov

A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 17, 2020

Study Completion Date

February 17, 2020

Conditions
Uterine Cervix Cancer
Interventions
DRUG

Nelfinavir

BIOLOGICAL

Cisplatin

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02363829 - A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA) | Biotech Hunter | Biotech Hunter